At HMC during my tenure, all plasma products—whole-blood and apheresis-derived were pathogen inactivated with riboflavin (Mirasol). In our software processes, I had options to release both Mirasol-treated and untreated (the latter in emergencies) and to aliquot either as needed. The same processes applied to COVID-19 convalescent plasma CCP except that they were performed in a quarantine production area. There were specific ISBT codes for CCP.

24/9/20